This event has no dates available for booking. Please contact the event organiser.

MELBOURNE - Medical Cannabis for Health Professionals 2.0


                                    
Medicinal cannabis was legalised in Australia in November 2016. The global legal cannabis market is expected to grow to over US$20 billion by 2020.

There is good clinical evidence that it may be of benefit in Chronic Pain, MS, Nausea in Cancer Related Chemotherapy and Drug Resistant Epilepsy.

Come and learn about the latest trends and scientific research in this exciting new field from a range of experts.

Medicinal cannabis was legalised in Australia in November 2016. The global legal cannabis market is expected to grow to over US$20 billion by 2020.

There is good clinical evidence that it may be of benefit in chronic pain, MS, nausea in cancer related chemotherapy and drug resistant epilepsy.

Come and learn about the latest trends and scientific research in this exciting new field from a range of experts.

 

PRESENTERS INCLUDE

Paul Mavor - Health House International
Paul is a pharmacist who has been researching the potential of medicinal cannabis as a treatment for several years. His company was granted the first medicinal cannabis import license in Australia and he is currently distributing medicinal cannabis products to eligible patients. Paul brings a wealth of knowledge from his hands-on research in the U.S., Canada and Israel. www.healthhouse.com.au

Dr Ian Brighthope - Nutrition Care Pharmaceuticals Pty. Ltd.
Ian is an Australian doctor with an interest in medical cannabis as a treatment option. He is also the founding president of the Australian College of Nutritional and Environmental Medicine and Founder of Nutrition Care Pharmaceuticals Pty. Ltd., a TGA licensed manufacturer of Complementary and Herbal Medicines that has developed markets in China, SE Asia and India. Has a sound appreciation of the scientific basis of herbal medicines, their cultivation, breeding, composition, extraction, GMP manufacturing to PICS standards and their clinical use. Interested in the development of the Cannabis industry in Australia from plant to patient, with a particular emphasis on its responsible prescription, Ian will present the evidence of its benefits from an experiential perspective in cancer patient care, pain management, treatment of addictions and inflammatory disorders.
www.nutritioncare.com.au/

Doctor Teresa Towpik - General Practitioner
Teresa is a Polish born doctor currently practicing in Katoomba NSW. As a GP for more than 30 years, Dr Towpik has prescribed thousands of drugs for patients, many of them opioids which can have severe side effects. Her research into cannabis has led her to believe it could be a much better form of pain relief. She is a cancer survivor and passionate about using medical cannabis as a treatment option. www.medihuanna.comAssociate Professor Jonathon Arnold - Lambert Initiative for Cannabinoid Therapeutics (Sydney University)
Jonathon is in charge of pre-clinical research at the Lambert Initiative and has published over 60 research papers that have received more than 2,000 citations. His first major discovery was that plant cannabinoids reverse resistance to anticancer drugs. He has also isolated several genes that modulate the effects of cannabinoids on the brain and contributed to Australia’s first cannabis potency study, showing that Australian street cannabis is among the most potent in the world. More recently he has published research on interplay between CBD and THC which may contribute to the ’entourage effect‘. www.sydney.edu.au/lambert/

Cameron Scadding - Source Certain
Cameron is an expert in supply chain integrity and ensuring that consumers get what is both promised and from the source claimed. www.sourcecertain.com

Rhys Cohen – Senior Project Officer at The Lambert Initiative (Sydney University)
Rhys acts as a key interface between the Lambert Initiative for Cannabinoid Therapeutics and government, regulators, industry and consumers.He responsible for leading a variety of projects within the Lambert Initiative to do with drug policy; the scheduling and rescheduling of cannabis products; NSW Health and TGA/ODC licensing; industry engagement; consumer outreach; and education. He is also responsible for the development of public policy positions for the Lambert Initiative relating to issues such as patient access. www.sydney.edu.au/lambert/

AMREP Lecture Theatre
55 Commercial Road, Melbourne, VIC 3000

Contact Details



A not for profit dedicated to lobbying, education and research in medicinal cannabis

Map
Contact Form

This event is currently closed and no contact details are available